

Symmetry Medical Inc.
Form NT 10-Q
November 09, 2012

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 12b-25

SEC FILE NUMBER
001-32374

NOTIFICATION OF LATE FILING CUSIP NUMBER
871-546-206

(Check one): Form 10-K Form 20-F Form 11-K x Form 10-Q Form 10-D Form N-SAR Form N-CSR
For Period Ended: September 29, 2012

- Transition Report on Form 10-K
- Transition Report on Form 20-F
- Transition Report on Form 11-K
- Transition Report on Form 10-Q
- Transition Report on Form N-SAR

For the Transition Period Ended: _____

Read Instruction (on back page) Before Preparing Form. Please Print or Type.

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

PART I — REGISTRANT INFORMATION

Symmetry Medical Inc.
Full Name of Registrant

Former Name if Applicable

3724 North State Road 15
Address of Principal Executive Office (*Street and Number*)

Warsaw, Indiana 46582
City, State and Zip Code

PART II — RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

- (a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense
The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
- x(b) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
-

PART III — NARRATIVE

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

The Company's Form 10-Q for the period ended September 29, 2012 was filed with the SEC on November 8, 2012 at 5:37 EST. Although the Company provided the Form 10-Q to the outside service provider six days prior to the filing deadline, the delay was caused by the service provider's failure to correctly XBRL detail tag, EDGARIZE and file the document in a timely manner.

(Attach extra Sheets if Needed)

PART IV — OTHER INFORMATION

- (1) Name and telephone number of person to contact in regard to this notification

Ronda L. Harris (574) 371-2270
(Name) (Area Code) (Telephone Number)

Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for (2) such shorter period that the registrant was required to file such report(s) been filed ? If answer is no, identify report(s).

Yes x No "

Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof ?

Yes x No "

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.
(3)

The Company's results in the third fiscal quarter of 2012 are substantially different than those of the same quarter in fiscal 2011 as a result of the Company's acquisition of the Codman & Shurtleff surgical instruments business from Johnson & Johnson, Inc. Further details regarding the acquisition and the impact on the Company's financial results is more completely disclosed and discussed within the Company's Form 10-Q, which was filed on November 8, 2012.

Symmetry Medical Inc.
(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its
behalf by the undersigned hereunto duly
authorized.

Date November 9, 2012 By. /s/ Ronda L. Harris

INSTRUCTION: The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative's authority to sign on behalf of the registrant shall be filed with the form.

ATTENTION
Intentional
misstatements or
omissions of fact
constitute
Federal Criminal
Violations (See
18 U.S.C. 1001).